OS was censored at 18 months because only a subgroup of nontransplanted patients was followed beyond 18 months. (A) OS was defined from the start of blinatumomab infusion until death. (B) OS was analyzed according to MRD response using the Kaplan-Meier method. (C) OS was analyzed according to alloHSCT status after blinatumomab using a Simon-Makuch 60-day landmark analysis. (D) OS was analyzed according to donor type for alloHSCT after blinatumomab treatment. Vertical bars indicate censoring.